How BMS Is Tackling Clinical Trial Diversity
Site Selection Is A Critical Component
The company’s director of clinical trial diversity strategy, Lorena Kuri, talked to Scrip about how she became interested in trial diversity and what BMS is doing to increase it.
You may also be interested in...
Project Site Selector will allow FDA Oncology Center of Excellence staff to discuss site selection process with industry and potentially help improve clinical trial diversity efforts.
PhRMA partnered with Deloitte to produce a report that included a survey of 31 member companies indicating that most had made significant investments in improving clinical trial diversity.
Individuals from pharma, biotech, technology and academia create shared database to facilitate development of therapeutic proteins that are unlikely to provoke immune reactions.